JP2004538258A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004538258A5 JP2004538258A5 JP2002572418A JP2002572418A JP2004538258A5 JP 2004538258 A5 JP2004538258 A5 JP 2004538258A5 JP 2002572418 A JP2002572418 A JP 2002572418A JP 2002572418 A JP2002572418 A JP 2002572418A JP 2004538258 A5 JP2004538258 A5 JP 2004538258A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- subject
- group
- wrinkle
- induction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims 60
- 150000001875 compounds Chemical class 0.000 claims 59
- 230000037303 wrinkles Effects 0.000 claims 36
- 230000006698 induction Effects 0.000 claims 33
- 150000003839 salts Chemical class 0.000 claims 18
- 150000002148 esters Chemical class 0.000 claims 11
- 230000002401 inhibitory effect Effects 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 230000027455 binding Effects 0.000 claims 7
- 206010036790 Productive cough Diseases 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- -1 methylphenoxy Chemical group 0.000 claims 6
- 210000003802 sputum Anatomy 0.000 claims 6
- 208000024794 sputum Diseases 0.000 claims 6
- 125000000129 anionic group Chemical group 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 230000000144 pharmacologic effect Effects 0.000 claims 5
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 210000002569 neuron Anatomy 0.000 claims 4
- 108010005551 GABA Receptors Proteins 0.000 claims 3
- 102000005915 GABA Receptors Human genes 0.000 claims 3
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 3
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 3
- 102000012276 GABA Plasma Membrane Transport Proteins Human genes 0.000 claims 2
- 108091006228 GABA transporters Proteins 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 229910017053 inorganic salt Inorganic materials 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- INAQBBFMGZBFDK-OAHLLOKOSA-N (3r)-3-amino-3-[3-(4-methylphenoxy)phenyl]propanoic acid Chemical compound C1=CC(C)=CC=C1OC1=CC=CC([C@H](N)CC(O)=O)=C1 INAQBBFMGZBFDK-OAHLLOKOSA-N 0.000 claims 1
- NVKJHUJOTYZSCP-CQSZACIVSA-N (3r)-3-azaniumyl-3-[3-[3-(trifluoromethyl)phenoxy]phenyl]propanoate Chemical compound [O-]C(=O)C[C@@H]([NH3+])C1=CC=CC(OC=2C=C(C=CC=2)C(F)(F)F)=C1 NVKJHUJOTYZSCP-CQSZACIVSA-N 0.000 claims 1
- DOHHGYXZPWMNKT-AWEZNQCLSA-N (3s)-3-amino-3-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)C[C@H](N)C1=CC=CC(OC=2C=CC=CC=2)=C1 DOHHGYXZPWMNKT-AWEZNQCLSA-N 0.000 claims 1
- UXSWIUULBPJEDJ-ZDUSSCGKSA-N (3s)-3-amino-3-[3-[2-(trifluoromethyl)phenoxy]phenyl]propanoic acid Chemical compound OC(=O)C[C@H](N)C1=CC=CC(OC=2C(=CC=CC=2)C(F)(F)F)=C1 UXSWIUULBPJEDJ-ZDUSSCGKSA-N 0.000 claims 1
- DQNYBJRIDPIZRQ-UHFFFAOYSA-N 2-[amino-(4-methoxyphenyl)methyl]propanedioic acid Chemical compound COC1=CC=C(C(N)C(C(O)=O)C(O)=O)C=C1 DQNYBJRIDPIZRQ-UHFFFAOYSA-N 0.000 claims 1
- GRBQNAGYLXGQCJ-UHFFFAOYSA-N 2-[amino-(4-methylphenyl)methyl]propanedioic acid Chemical compound CC1=CC=C(C(N)C(C(O)=O)C(O)=O)C=C1 GRBQNAGYLXGQCJ-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 1
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 claims 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 1
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 claims 1
- 125000005110 aryl thio group Chemical group 0.000 claims 1
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 125000006267 biphenyl group Chemical group 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical compound [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 230000009920 chelation Effects 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000002858 neurotransmitter agent Substances 0.000 claims 1
- 125000006501 nitrophenyl group Chemical group 0.000 claims 1
- 125000003884 phenylalkyl group Chemical group 0.000 claims 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 claims 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 0 OC1=*C(Cc2ccccc2)C1 Chemical compound OC1=*C(Cc2ccccc2)C1 0.000 description 3
- OXBZNIRABQKQTO-UHFFFAOYSA-N NC(CC(O)=O)c1cc(Oc(cc2)ccc2Cl)ccc1 Chemical compound NC(CC(O)=O)c1cc(Oc(cc2)ccc2Cl)ccc1 OXBZNIRABQKQTO-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27561801P | 2001-03-13 | 2001-03-13 | |
| PCT/CA2002/000363 WO2002073208A2 (en) | 2001-03-13 | 2002-03-13 | Anti-epileptogenic agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007150044A Division JP2007302678A (ja) | 2001-03-13 | 2007-06-06 | 抗癲癇誘発剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004538258A JP2004538258A (ja) | 2004-12-24 |
| JP2004538258A5 true JP2004538258A5 (enExample) | 2006-01-12 |
Family
ID=23053121
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002572418A Withdrawn JP2004538258A (ja) | 2001-03-13 | 2002-03-13 | 抗癲癇誘発剤 |
| JP2007150044A Pending JP2007302678A (ja) | 2001-03-13 | 2007-06-06 | 抗癲癇誘発剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007150044A Pending JP2007302678A (ja) | 2001-03-13 | 2007-06-06 | 抗癲癇誘発剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20030194375A1 (enExample) |
| EP (1) | EP1386166A2 (enExample) |
| JP (2) | JP2004538258A (enExample) |
| CN (1) | CN1774635A (enExample) |
| CA (1) | CA2440834A1 (enExample) |
| IL (1) | IL157845A0 (enExample) |
| MX (1) | MXPA03008164A (enExample) |
| WO (1) | WO2002073208A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040208875A1 (en) * | 1995-03-15 | 2004-10-21 | Queen's University At Kingston | Method for treating amyloidosis |
| KR20070094996A (ko) * | 1999-04-28 | 2007-09-27 | 뉴로겜 인터내셔널 리미티드 | 아밀로이드증 치료용 조성물 및 방법 |
| HK1051137A1 (zh) * | 1999-07-09 | 2003-07-25 | Isis Innovation Limited | 抑制疾病的化合物和製備移植用的細胞 |
| BR0210357A (pt) * | 2001-06-11 | 2004-06-29 | Shire Biochem Inc | Composto e métodos para o tratamento ou a prevenção de infecções pelo flavivìrus |
| US8329924B2 (en) * | 2001-06-11 | 2012-12-11 | Vertex Pharmaceuticals (Canada) Incorporated | Compounds and methods for the treatment or prevention of Flavivirus infections |
| US7355042B2 (en) | 2001-10-16 | 2008-04-08 | Hypnion, Inc. | Treatment of CNS disorders using CNS target modulators |
| NI200300043A (es) | 2002-03-28 | 2003-11-05 | Warner Lambert Co | AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA. |
| US7244764B2 (en) | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US20070010573A1 (en) | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| JP2007506726A (ja) * | 2003-09-25 | 2007-03-22 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | α２δ−タンパク質に対する親和性を有するアミノ酸の使用方法 |
| CA2565095A1 (en) * | 2004-05-17 | 2005-12-08 | William S. Brusilow | Decreasing brain neuronal glutamate levels using alpha-keto branched chain amino acids |
| BRPI0519243A2 (pt) | 2004-12-22 | 2009-01-06 | Neurochem Int Ltd | mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide |
| TW200716088A (en) * | 2005-04-15 | 2007-05-01 | Neurochem Int Ltd | Formulations and methods for treating amyloidosis |
| WO2007023389A2 (en) * | 2005-07-21 | 2007-03-01 | Neurochem (International) Limited | Polymorphic forms of 3-amino-1-propanesulfonic acid |
| MX2008008213A (es) * | 2005-12-22 | 2008-09-03 | Neurochem Int Ltd | Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias. |
| MX339684B (es) | 2006-10-12 | 2016-06-06 | Bhi Ltd Partnership | Metodos, compuestos, composiciones y vehiculos para suministrar el acido 3-amino-1-propanosulfonico. |
| MX2009006768A (es) * | 2006-12-22 | 2009-08-31 | Bellus Health Int Ltd | Metodos, compuestos, y composiciones para tratar trastornos metabolicos y diabetes. |
| WO2009079373A2 (en) | 2007-12-14 | 2009-06-25 | The Regents Of The University Of California | Inhibitors of calcium-activated chloride channels |
| ES2613729T3 (es) * | 2008-02-07 | 2017-05-25 | Marquette University | Cisteína y profármacos de cisteína para tratar la esquizofrenia y reducir los deseos compulsivos por los fármacos |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2461842A (en) * | 1943-02-26 | 1949-02-15 | Sharples Chemicals Inc | Condensation of nitriles with amides and the production of beta-alanine |
| NZ194348A (en) * | 1979-07-26 | 1982-09-14 | Merrell Toraude & Co | Fluorinated methyl-beta-alanine derivatives and pharmaceutical compositions |
| US4255448A (en) * | 1979-09-10 | 1981-03-10 | Wisconsin Alumni Research Foundation | Method for reducing epileptiform activity |
| JPS6124552A (ja) * | 1984-07-13 | 1986-02-03 | Kuraray Co Ltd | γ−アミノ酪酸誘導体およびその製造法 |
| US4906779A (en) * | 1986-07-10 | 1990-03-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
| DE3737399A1 (de) * | 1987-11-04 | 1989-05-18 | Schwabe Willmar Gmbh & Co | Aminosaeureester, verfahren zu ihrer herstellung und ihre verwendung |
| US5252576A (en) * | 1988-07-18 | 1993-10-12 | Yamasa Shoyu Kabushiki Kaisha | 1-amino-5-halogenouracils, process for their preparation, and central nervous system depressants containing same as active ingredient |
| GB8926512D0 (en) * | 1989-11-23 | 1990-01-10 | Pfizer Ltd | Therapeutic agents |
| US5648369A (en) * | 1991-11-20 | 1997-07-15 | University Of Kentucky Research Foundation | Aminoalkylpyridine compounds which are useful as anitconvulsant drugs, excitatory amino acid inhibitors and NMDA sigma receptor antagonists |
| US6306909B1 (en) * | 1997-03-12 | 2001-10-23 | Queen's University At Kingston | Anti-epileptogenic agents |
-
2002
- 2002-03-13 CN CNA028098706A patent/CN1774635A/zh active Pending
- 2002-03-13 JP JP2002572418A patent/JP2004538258A/ja not_active Withdrawn
- 2002-03-13 EP EP02708078A patent/EP1386166A2/en not_active Withdrawn
- 2002-03-13 MX MXPA03008164A patent/MXPA03008164A/es not_active Application Discontinuation
- 2002-03-13 IL IL15784502A patent/IL157845A0/xx unknown
- 2002-03-13 CA CA002440834A patent/CA2440834A1/en not_active Abandoned
- 2002-03-13 WO PCT/CA2002/000363 patent/WO2002073208A2/en not_active Ceased
- 2002-10-15 US US10/272,249 patent/US20030194375A1/en not_active Abandoned
-
2007
- 2007-06-06 JP JP2007150044A patent/JP2007302678A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004538258A5 (enExample) | ||
| JP2005526011A5 (enExample) | ||
| Fagg | L-Glutamate, excitatory amino acid receptors and brain function | |
| Garner et al. | Butorphanol-mediated antinociception in mice: partial agonist effects and mu receptor involvement | |
| US6306909B1 (en) | Anti-epileptogenic agents | |
| US20110257134A1 (en) | CO-CRYSTALS OF TRAMADOL AND NSAIDs | |
| HRP20120154T1 (hr) | HETEROCIKLIČKI INHIBITORI MEK-a I METODE NJIHOVE UPORABE | |
| KR910000659A (ko) | 이미다졸릴-알케노산 | |
| Quarles | Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues | |
| MY130830A (en) | Inhibitors | |
| JP2015529802A5 (enExample) | ||
| JP2006520392A5 (enExample) | ||
| CA2550660A1 (en) | Florfenicol prodrug having improved water solubility | |
| MA29416B1 (fr) | Inhibiteurs d'age | |
| JP2015523385A5 (enExample) | ||
| US20030194375A1 (en) | Anti-epileptogenic agents | |
| JP2014505017A5 (enExample) | ||
| JP2006528182A5 (enExample) | ||
| MY157122A (en) | 2 - [[[2 -[(hydroxyacetyl) amino]- 4 -pyridinyl] methyl]thio]- n -[4 - (trifluoromethoxy) phenyl]- 3 -pyridinecarboxamide benzene-sulfonate, crystal of same, polymorph thereof, and processes for production thereof | |
| JP2008533063A5 (enExample) | ||
| Deprez et al. | New potent calcimimetics: II. Discovery of benzothiazole trisubstituted ureas | |
| ZA200300514B (en) | Novel compounds and their use as glycine transport inhibitors. | |
| JP2008534541A5 (enExample) | ||
| TW427973B (en) | Novel compounds as excitatory amino acid receptor antagonists, process for the preparation thereof, and pharmaceutical compositions comprising the compounds | |
| RU2009104060A (ru) | Новые оптически активные соединения фенилэтаноламинов и способ их получнеия |